This is the first product launch under the previously announced exclusive licensing agreement between Nevakar Injectables, and Endo's subsidiary, Endo Ventures.
Through a partnership with RxRevu, FDB Vela brings real-time pharmacy benefit information to e-prescribing workflows embedded seamlessly within an EHR.
Cortrophin Gel is indicated for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis and excess urinary protein due to nephrotic syndrome.
The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.